These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 39065577)
21. [Effect of siRNA inhibiting HPV16 E6 gene expression on proliferation and cell cycle of cervical cancer cell line CaSki]. Guan LL; Peng ZL; Niu XY; Wang HJ; Wang DQ Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Jan; 39(1):10-4. PubMed ID: 18390189 [TBL] [Abstract][Full Text] [Related]
22. Inhibition of cervical cancer cell growth in vitro and in vivo by lentiviral-vector mediated shRNA targeting the common promoter of HPV16 E6 and E7 oncogenes. Zhou J; Li B; Peng C; Wang F; Fu Z; Zhou C; Hong D; Ye F; Lü W; Xie X Antiviral Res; 2013 May; 98(2):305-13. PubMed ID: 23523766 [TBL] [Abstract][Full Text] [Related]
23. Enhanced endosomal/lysosomal escape by distearoyl phosphoethanolamine-polycarboxybetaine lipid for systemic delivery of siRNA. Li Y; Cheng Q; Jiang Q; Huang Y; Liu H; Zhao Y; Cao W; Ma G; Dai F; Liang X; Liang Z; Zhang X J Control Release; 2014 Feb; 176():104-14. PubMed ID: 24365128 [TBL] [Abstract][Full Text] [Related]
24. Promoting Vaginal Distribution of E7 and MCL-1 siRNA-Silencing Nanoparticles for Cervical Cancer Treatment. Lechanteur A; Furst T; Evrard B; Delvenne P; Piel G; Hubert P Mol Pharm; 2017 May; 14(5):1706-1717. PubMed ID: 28350964 [TBL] [Abstract][Full Text] [Related]
25. E6^E7, a novel splice isoform protein of human papillomavirus 16, stabilizes viral E6 and E7 oncoproteins via HSP90 and GRP78. Ajiro M; Zheng ZM mBio; 2015 Feb; 6(1):e02068-14. PubMed ID: 25691589 [TBL] [Abstract][Full Text] [Related]
26. Human Papillomavirus E6/E7-Specific siRNA Potentiates the Effect of Radiotherapy for Cervical Cancer in Vitro and in Vivo. Jung HS; Rajasekaran N; Song SY; Kim YD; Hong S; Choi HJ; Kim YS; Choi JS; Choi YL; Shin YK Int J Mol Sci; 2015 May; 16(6):12243-60. PubMed ID: 26035754 [TBL] [Abstract][Full Text] [Related]
27. Silencing of HPV 18 oncoproteins With RNA interference causes growth inhibition of cervical cancer cells. Lea JS; Sunaga N; Sato M; Kalahasti G; Miller DS; Minna JD; Muller CY Reprod Sci; 2007 Jan; 14(1):20-8. PubMed ID: 17636212 [TBL] [Abstract][Full Text] [Related]
28. PEGylated DC-Chol/DOPE cationic liposomes containing KSP siRNA as a systemic siRNA delivery Carrier for ovarian cancer therapy. Lee J; Ahn HJ Biochem Biophys Res Commun; 2018 Sep; 503(3):1716-1722. PubMed ID: 30049442 [TBL] [Abstract][Full Text] [Related]
29. Stealth monoolein-based nanocarriers for delivery of siRNA to cancer cells. Oliveira AC; Raemdonck K; Martens T; Rombouts K; Simón-Vázquez R; Botelho C; Lopes I; Lúcio M; González-Fernández Á; Real Oliveira ME; Gomes AC; Braeckmans K Acta Biomater; 2015 Oct; 25():216-29. PubMed ID: 26225736 [TBL] [Abstract][Full Text] [Related]
30. Human papillomavirus oncoproteins differentially modulate epithelial-mesenchymal transition in 5-FU-resistant cervical cancer cells. Vishnoi K; Mahata S; Tyagi A; Pandey A; Verma G; Jadli M; Singh T; Singh SM; Bharti AC Tumour Biol; 2016 Oct; 37(10):13137-13154. PubMed ID: 27449048 [TBL] [Abstract][Full Text] [Related]
31. Effects of PEG anchors in PEGylated siRNA lipoplexes on in vitro gene‑silencing effects and siRNA biodistribution in mice. Hattori Y; Tamaki K; Sakasai S; Ozaki KI; Onishi H Mol Med Rep; 2020 Nov; 22(5):4183-4196. PubMed ID: 33000194 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of the anti-cancer efficacy of lipid nanoparticles containing siRNA against HPV16 E6/E7 combined with cisplatin in a xenograft model of cervical cancer. Kang SW; Kang OJ; Lee JY; Kim H; Jung H; Kim H; Lee SW; Kim YM; Choi EK PLoS One; 2024; 19(2):e0298815. PubMed ID: 38363779 [TBL] [Abstract][Full Text] [Related]
33. Human Papillomavirus E6/E7 and Long Noncoding RNA TMPOP2 Mutually Upregulated Gene Expression in Cervical Cancer Cells. He H; Liu X; Liu Y; Zhang M; Lai Y; Hao Y; Wang Q; Shi D; Wang N; Luo XG; Ma W; Zhang TC J Virol; 2019 Apr; 93(8):. PubMed ID: 30728257 [TBL] [Abstract][Full Text] [Related]
34. Disruption of repressive p130-DREAM complexes by human papillomavirus 16 E6/E7 oncoproteins is required for cell-cycle progression in cervical cancer cells. Nor Rashid N; Yusof R; Watson RJ J Gen Virol; 2011 Nov; 92(Pt 11):2620-2627. PubMed ID: 21813705 [TBL] [Abstract][Full Text] [Related]
35. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody. Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF mBio; 2021 Jan; 12(1):. PubMed ID: 33468698 [TBL] [Abstract][Full Text] [Related]
36. HPV16 E6 promotes cell proliferation, migration, and invasion of human cervical cancer cells by elevating both EMT and stemness characteristics. Lu Y; Chen Y; Zhang Z; Li M; Chen X; Tu K; Li L Cell Biol Int; 2022 Apr; 46(4):599-610. PubMed ID: 34957655 [TBL] [Abstract][Full Text] [Related]
37. Development and characterization of siRNA lipoplexes: Effect of different lipids, in vitro evaluation in cancerous cell lines and in vivo toxicity study. Khatri N; Baradia D; Vhora I; Rathi M; Misra A AAPS PharmSciTech; 2014 Dec; 15(6):1630-43. PubMed ID: 25145330 [TBL] [Abstract][Full Text] [Related]
38. Induction of cell death in human papillomavirus 18-positive cervical cancer cells by E6 siRNA. Yamato K; Fen J; Kobuchi H; Nasu Y; Yamada T; Nishihara T; Ikeda Y; Kizaki M; Yoshinouchi M Cancer Gene Ther; 2006 Mar; 13(3):234-41. PubMed ID: 16138119 [TBL] [Abstract][Full Text] [Related]
39. 3-(2-Chloropropyl amide)-4-methoxy-N-phenylbenzamide inhibits expression of HPV oncogenes in human cervical cancer cell. Han F; Li Y; Lu Q; Ma L; Wang H; Jiang J; Li Z; Li Y Virol J; 2017 Jul; 14(1):145. PubMed ID: 28754129 [TBL] [Abstract][Full Text] [Related]
40. Interfering Human Papillomavirus E6/E7 Oncogenes in Cervical Cancer Cells Inhibits the Angiogenesis of Vascular Endothelial Cells via Increasing miR-377 in Cervical Cancer Cell-Derived Microvesicles. Zhang Y; Liu Y; Guo X; Hu Z; Shi H Onco Targets Ther; 2020; 13():4145-4155. PubMed ID: 32523352 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]